Christelle Jouannaud
Institut Jean Godinot(FR)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer survivorship and care
Most-Cited Works
- → 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial(2013)337 cited
- → Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort(2018)277 cited
- → Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study(2005)211 cited
- → Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort(2019)210 cited
- → Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016(2020)186 cited
- → Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer(2018)167 cited
- → Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk(2020)136 cited
- → Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort(2021)127 cited
- → 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial(2019)126 cited
- → Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact(2014)122 cited